About
Parkinson's Disease Treatment
Touch Brain has developed novel formulations of existing drugs that result in unique activity for the treatment of large-market central nervous system diseases. Touch Brain's technology is based on proprietary formulations for intranasal administration and novel combinations of approved drugs. The intranasal route holds many advantages including increased bio-availability, elimination of first-pass metabolism, improvement of brain targeting, convenience, and patient compliance.
Identity
| Name | Touch Brain |
|---|---|
| Slug | touch-brain |
| Type / kind | startup |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoJH1yqMKDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Jan 2019 ceased to operate |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | North District |
| HQ city | Yokne'am Illit |
| HQ address | Ha-Tsmikha Street 1, Yokne'am Illit, Israel |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
parkinsonmedical-technologiespharmaceuticalstreatments
Funding
| Total raised | — |
|---|---|
| Current stage | Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}